A multidisciplinary team of doctors at Kilpauk Medical College (KMC), Chennai, successfully treated a 32-year-old pregnant woman diagnosed with thrombotic thrombocytopenic purpura (TTP), a rare and potentially life-threatening blood disorder. The coordinated treatment allowed the patient to safely deliver a healthy baby, according to reports from The Hindu and DT Next.
The patient was admitted with severe complications related to TTP, a condition that can cause dangerous blood clot formation throughout the body and is considered particularly high-risk during pregnancy.
Doctors from multiple specialties collaborated to stabilize the patient and manage the disorder while ensuring the safety of both mother and fetus.
Thrombotic thrombocytopenic purpura is a rare blood disorder characterized by abnormal clot formation in small blood vessels throughout the body.
The condition occurs when the enzyme ADAMTS13, which normally regulates blood clotting, becomes severely deficient or inhibited. This leads to excessive platelet aggregation and the formation of microscopic clots in the circulation.
These clots can reduce blood flow to vital organs such as the brain, kidneys, and heart.
According to medical literature, the key features of TTP include:
Low platelet count (thrombocytopenia)
Microvascular blood clots
Hemolytic anemia (destruction of red blood cells)
Neurological symptoms
Kidney dysfunction
Untreated TTP can rapidly progress and may be fatal.
Pregnancy itself causes changes in the body’s coagulation system, which can increase the risk of clotting disorders.
When TTP occurs during pregnancy, it can lead to serious complications such as:
Severe anemia
Organ damage due to blocked blood vessels
Placental complications affecting fetal oxygen supply
Risk of maternal mortality if untreated
Early diagnosis and rapid treatment are therefore essential in managing TTP during pregnancy.
Doctors at Kilpauk Medical College implemented a multidisciplinary treatment strategy to manage the patient’s condition.
The medical management included:
The patient received platelet transfusions to help stabilize dangerously low platelet levels. Platelets are blood components responsible for clotting and preventing bleeding.
Doctors also used immunotherapy to control the immune-mediated process causing TTP, which helps reduce the destruction of platelets and restore the function of the ADAMTS13 enzyme involved in blood clot regulation.
These treatments helped stabilize the patient and reduce the life-threatening clotting complications associated with the disorder.
The treatment involved coordination between specialists from several departments including:
Obstetrics and gynecology
Hematology
Critical care
Neonatology
Such collaborative care is often required in rare high-risk pregnancy complications to balance maternal treatment needs with fetal safety.
Following medical stabilization, the patient was able to continue pregnancy under close monitoring before successfully delivering a healthy baby.
Rare hematological disorders such as TTP require rapid diagnosis and specialized treatment.
Medical experts note that early intervention significantly improves survival rates for both mothers and babies when TTP occurs during pregnancy.
Advances in diagnostic techniques and targeted therapies have improved outcomes in cases that were historically associated with very high mortality.
Reference
Howells Lara, Maxine Lissack, Clare Wykes, Mari R. Thomas, and Marie Scully. “Recombinant ADAMTS-13 for Congenital and Immune Thrombotic Thrombocytopenic Purpura in Pregnancy.” Blood Vessels, Thrombosis & Hemostasis 2, no. 4 (2025): 100101. https://doi.org/10.1016/j.bvth.2025.100101.
